Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 2/3 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Conditions

Breast Neoplasms 23Neutropenia 22Neoplasms 7Chemotherapy-induced Neutropenia 7Lymphoma, Non-Hodgkin 6Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Lymphoma 3Fever 3Febrile Neutropenia 3Colorectal Neoplasms 3Rectal Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myeloid, Acute 1

Interventions

pegfilgrastim 7NPI 2358 4Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Docetaxel 3balugrastim 2Drug Therapy 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Chemotherapy-induced Neutropenia × pegfilgrastim × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

NCT00837265 2024-04-03

NEUGR-002

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2/3 Completed
334 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

NCT03559387 2019-02-12

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Prolong Pharmaceuticals

Phase 2 Terminated
9 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡